Global PARP Inhibitors Market

Report ID : 1169 | Published : 2021-07-28 | Pages: 140 | Format: PDF/EXCEL

Poly ADP-ribose polymerase or PARP inhibitor is a constituent that blocks the PARP enzyme in the cell. During cancer, DNA damage occurs. Inhibiting or blocking PARP helps the tumor cells in restoring their damaged part of DNA.  Various forms of cancer are more reliant on PARP than regular cells, building PARP an attractive target for cancer treatment. PARP inhibitors seem to enhance progression-free endurance in women with recurring platinum-sensitive ovarian cancer, as shown mainly by olaparib added to conventional treatment. the growing prevalence of cancer and rising demand for effective treatment solutions are expected to boost the growth of the market substantially over the forecast period.  According to CDC estimations in 2024 about 25.4 million cases of cancer are estimated to register in the U.S. only. The growing prevalence of cancer is increasing demand for advanced treatment in the coming years. Moreover, the growing death owing to cancer, and the rising number of new cases are expected to boost the growth of market PARP inhibitors significantly.

Currently, the PARP inhibitors are approved for only a few indications including, ovarian cancer, breast cancer, prostate, and pancreatic cancer. However, various drugs are under development stages for a different indication. The presence of numerous drugs under different stages of is expected to generate immense opportunity for the PARP inhibitors market growth over the forecast period. The global PARP inhibitors market size is expected to reach US$ xx million by 2028, growing at a CAGR of xx% over the forecast period. The growing strategic collaborations among the key players operating in the market to boost their pipeline product growth is expected to propel the market growth significantly. For instance, in January 2019, GlaxoSmithKline has acquired TESARO to expand its ovarian cancer portfolio. The acquisition allows GSK to marketing rights for Zejula (niraparib), an oral PARP inhibitor for the ovarian cancer treatment. However, the high cost of PARP inhibitors owing to the high cost of research and development activities may affect the growth of the market.

The Global PARP Inhibitors Market is segmented on the basis of product, application, and region. Based on the product, the market is segmented into Olaparib (Lynparza), Niraparib (Zejula), Talazoparib (Talzenna), Rucaparib (Rubraca), Veliparib, and Other Pipeline Drugs. In 2019, Olaparib (Lynparza) accounted for the largest share in the global PARP inhibitors market owing to its approval in major countries. Based on the application, the market is segmented into, breast cancer, ovarian cancer, and prostate and pancreatic cancer. Based on the region, the market is studied across North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Among them, North America, and Europe are estimated to account for the high share in the PARP inhibitors market globally. The increasing prevalence of sloid tumors in the regions and the presence of approved PARP inhibitors are contributing significantly to the growth of the market. Additionally, the presence of a large number of biopharmaceutical companies operating in the market and their strong pipeline are expected to propel the growth of the market over the estimated timeframe. In terms of growth rate, Asia Pacific is expected to register a high CAGR from 2020 to 2028. The growing healthcare expenditure and rising research and development activities are expected to boost the growth of the market in the Asia Pacific.

The key players of this market include Johnson & Johnson, GlaxoSmithKline Plc., Clovis Oncology Inc., Pfizer, Inc., AbbVie Inc., Merck KGaA, Genentech, Inc., Artios Pharma, Sierra Oncology, Inc., KaryopharmTherapeutics Inc., Repare Therapeutics Inc., Ono Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Bristol Myers Squibb, 2X Oncology, Cephalon, AstraZeneca Plc., Checkpoint Therapeutics, Eisai Co. Ltd, IMPACT Therapeutics, Jeil Pharmaceuticals, KuDOS Pharmaceuticals, Kyowa Hakko Kirin, Lead Therapeutics, Shanghai De Novo Pharmatech, SyntheX, and Tesaro among others. The growing mergers and acquisition among key players operating in the market are expected to foster market growth significantly in the coming years.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global PARP Inhibitors Market Snapshot

Chapter 4. Global PARP Inhibitors Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Penetration & Growth Prospect Mapping

4.6. Clinical Trial/Pipeline Analysis

4.7. Industry Analysis – Porter’s Five Forces Analysis

4.8. Competitive Landscape & Market Share Analysis

4.9. Technology Advancement in PARP Inhibitors

4.10. Key Trends in the Market

Chapter 5. Market Segmentation 1: Product Estimates & Trend Analysis

5.1. Product Type & Market Share, 2019 & 2028

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2018 to 2028 for the following Product:

5.2.1. Niraparib (Zejula)

5.2.2. Olaparib (Lynparza)

5.2.3. Rucaparib (Rubraca)

5.2.4. Talazoparib (Talzenna)

5.2.5. Veliparib

5.2.6. Other Pipeline Drugs

Chapter 6. PARP Inhibitors Market Segmentation 2: Application Estimates & Trend Analysis

6.1. Application Analysis & Market Share, 2019 & 2028

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2028 for the following Application:

6.2.1. Ovarian Cancer

6.2.2. Breast cancer

6.2.3. Prostate and Pancreatic Cancer

Chapter 7. PARP Inhibitors Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America PARP Inhibitors Market revenue (US$ Million) estimates and forecasts by product, 2019-2028

7.1.2. North America PARP Inhibitors Market revenue (US$ Million) estimates and forecasts by application, 2019-2028

7.1.3. North America PARP Inhibitors Market revenue (US$ Million) estimates and forecasts by country, 2019-2028

7.1.3.1. U.S.

7.1.3.2. Canada

7.2. Europe

7.2.1. Europe PARP Inhibitors Market revenue (US$ Million) by product, 2019-2028

7.2.2. Europe PARP Inhibitors Market revenue (US$ Million) by application, 2019-2028

7.2.3. Europe PARP Inhibitors Market revenue (US$ Million) by country, 2019-2028

7.2.3.1. Germany

7.2.3.2. Poland

7.2.3.3. France

7.2.3.4. Italy

7.2.3.5. Spain

7.2.3.6. UK

7.2.3.7. Rest of Europe

7.3. Asia Pacific

7.3.1. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by product, 2019-2028

7.3.2. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by application, 2019-2028

7.3.3. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by country, 2019-2028

7.3.3.1. China

7.3.3.2. India

7.3.3.3. Japan

7.3.3.4. Australia

7.3.3.5. Rest of Asia Pacific

7.4. Latin America

7.4.1. Latin America PARP Inhibitors Market revenue (US$ Million) by product, (US$ Million)

7.4.2. Latin America PARP Inhibitors Market revenue (US$ Million) by Application, (US$ Million)

7.4.3. Latin America PARP Inhibitors Market revenue (US$ Million) by country, (US$ Million) 2019-2028

7.4.3.1. Brazil

7.4.3.2. Rest of Latin America

7.5. MEA

7.5.1. MEA revenue PARP Inhibitors Market revenue (US$ Million) by product, (US$ Million) 2019-2028

7.5.2. MEA revenue PARP Inhibitors Market revenue (US$ Million) by country, (US$ Million) 2019-2028

7.5.2.1. South Africa

7.5.2.2. Rest of MEA

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. AstraZeneca Plc.

8.2.2. Johnson & Johnson

8.2.3. GlaxoSmithKline Plc.

8.2.4. Pfizer, Inc.

8.2.5. Clovis Oncology Inc.

8.2.6. AbbVie Inc.

8.2.7. Bristol Myers Squibb

8.2.8. Merck KGaA

8.2.9. Genentech, Inc.

8.2.10. Artios Pharma

8.2.11. Repare Therapeutics Inc.

8.2.12. Sierra Oncology, Inc.

8.2.13. KaryopharmTherapeutics Inc.

8.2.14. Ono Pharmaceutical Co., Ltd.

8.2.15. Jiangsu Hengrui Medicine Co., Ltd.

8.2.16. 2X Oncology

8.2.17. Cephalon

8.2.18. Checkpoint Therapeutics

8.2.19. Eisai Co. Ltd

8.2.20. IMPACT Therapeutics

8.2.21. Jeil Pharmaceuticals

8.2.22. KuDOS Pharmaceuticals

8.2.23. Kyowa Hakko Kirin

8.2.24. Lead Therapeutics

8.2.25. Shanghai De Novo Pharmatech

8.2.26. SyntheX

8.2.27. Tesaro

8.2.28. Other Prominent Players

Global PARP Inhibitors Market Segmentation:

Global PARP Inhibitors Market by Product

  • Niraparib (Zejula)
  • Olaparib (Lynparza)
  • Rucaparib (Rubraca)
  • Talazoparib (Talzenna)
  • Veliparib
  • Other Pipeline Drugs

Global PARP Inhibitors Market by Indication

  • Ovarian Cancer
  • Breast cancer
  • Prostate and Pancreatic Cancer

Global PARP Inhibitors Market Based on Region

  • Europe PARP Inhibitors Market by Country
    • Germany
    • Poland
    • France
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • North America PARP Inhibitors Market by Country
    • U.S.
    • Canada
  • Asia Pacific PARP Inhibitors Market by Country
    • India
    • China
    • Japan
    • Australia
    • Rest of Asia Pacific
  • Latin America PARP Inhibitors Market by Country
    • Brazil
    • Rest of Latin America
  • Middle East & Africa PARP Inhibitors Market by Country
    • South Africa
    • Rest of MEA

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients